Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 4/20 | 0.88 |
| ▸ | USP2 | O75604 | 2/20 | 0.88 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16583523 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL2401189 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL17417853 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL6853620 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL2734323 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL10601682 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| SCHEMBL3047 | 0.94 | INMT (1.00) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| Iodide SCHEMBL23365018 | 0.91 | INMT (0.95) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| Bromide SCHEMBL8469764 | 0.91 | INMT (0.95) | INMTUSP2ACHESMN1; SMN2TDP1 | |
| Ammonia Solution, Strong SCHEMBL6834929 | 0.91 | INMT (0.95) | INMTUSP2ACHESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344048-B2 | Epoxy resin-forming liquid preparation containing inorganic particle | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100137475-A1 | EPOXY RESIN-FORMING LIQUID PREPARATION CONTAINING INORGANIC PARTICLE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2166037-A1 | EPOXY RESIN-FORMING LIQUID PREPARATION CONTAINING INORGANIC PARTICLE | Nissan Chemical Industries, Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050101653-A1 | Combination therapy for the treatment of migraine | SANDS GEORGE H (US) | 2005-05-12 | — | — | US | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6555540-B1 | Treatment of diabetic complications such as neuropathy, nephropathy, retinopathy and cardiomyopathy; for example zopolrestat and rofecoxib | PFIZER INC | 2003-04-29 | — | — | US | disclosed |
| US-6476042-B1 | Combination therapy for the treatment of migraine | PFIZER INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1064966-A2 | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1051995-A2 | 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101653-A1 | Combination therapy for the treatment of migraine | HTR1A, HTR2A, HTR1B | INMT 645/4885USP2 2393/4885ACHE 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.